Seventy-Eighth Oregon Legislative Assembly – 2015 Regular Session Legislative Fiscal Office

Only Impacts on Original or Engrossed Versions are Considered Official

Prepared by:	Kim To
Reviewed by:	Linda Ames, Matt Stayner
Date:	4/23/2015

Measure Description:

Directs Oregon Health Authority, Oregon Medical Board and Board of Nursing to study clinical guidance regarding Lyme disease and report findings to Legislature

Government Unit(s) Affected:

Oregon Health Authority (OHA), Oregon Medical Board, Board of Nursing

Local Government Mandate:

This bill does not affect local governments' service levels or shared revenues sufficient to trigger Section 15, Article XI of the Oregon Constitution.

Analysis:

Senate Bill 916 directs the Oregon Health Authority, the Oregon Medical Board, and the Oregon State Board of Nursing to study clinical guidance regarding Lyme disease and the health outcomes related to the clinical guidance and report these findings to a committee of the legislature by March 1, 2016.

The fiscal impact of this bill is indeterminate. As written, it is unclear what is expected from these three agencies. If all that is expected of these three agencies is to do a literature search of existing materials on Lyme disease and the health outcomes of existing clinical guidance, and to report these findings to a legislative committee, the fiscal impact of the bill to these agencies is minimal. All three agencies would reprioritize existing staff and resources to carry out this work and report to the legislature.

However, if the intent is for OHA to include clinical recommendations for Lyme disease in its contract with the Center for Evidence-based Practice (EPC), OHA may need approximately \$63,400 General Fund resources to modify its existing EPC contract to reprioritize its topic nomination to include Lyme disease. In addition, OHA reports that typically the cost of producing a Clinical Guidance is \$35,000 and the cost of producing a Clinical Practice Guideline is \$65,000.